Christine Dos Santos1, Laurent Essioux1, 5, Cécile Teinturier2, Maïté Tauber3, Vincent Goffin4
& Pierre Bougnères1, 21
U561 INSERM, Saint Vincent de Paul Hospital, Paris V University, 82 Avenue Denfert-Rochereau, 75014 Paris, France.
2
Department of Pediatric Endocrinology, Saint Vincent de Paul Hospital, Paris V University, 82 Avenue Denfert-Rochereau, 75014 Paris, France.
3
Unité d'Endocrinologie, Children's Hospital, Toulouse, France.
4
U584 INSERM, Necker, Paris V University, Paris, France.
5
Present address: F. Hoffmann-La Roche, Roche Genetics, Basel, Switzerland.
Correspondence should be addressed to Pierre Bougnères bougneres@paris5.inserm.fr
30% higher than through full-length GHR homodimers (P < 0.0001). One-half of Europeans are hetero- or homozygous with respect to the allele encoding the d3-GHR isoform, which is dominant over the full-length isoform. These observations suggest that the polymorphism in exon 3 of GHR is important in growth hormone pharmacogenetics.
